Dr. Reddy's Laboratories Limited (DRREDDY.BO)
| Previous Close | 5,871.00 |
| Open | 5,891.00 |
| Bid | 5,872.80 x 0 |
| Ask | 5,878.85 x 0 |
| Day's Range | 5,862.15 - 5,964.65 |
| 52 Week Range | 4,383.40 - 6,505.50 |
| Volume | |
| Avg. Volume | 13,929 |
| Market Cap | 977.911B |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | 17.55 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 40.00 (0.68%) |
| Ex-Dividend Date | Jul 15, 2024 |
| 1y Target Est | N/A |
- Business Wire
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
HYDERABAD, India, May 07, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
